Introduction: Introduction: Introduction:Baiji Divine anti-PD-1 antibody is expected to recently approved new indications;based CaptH NGS ofPV liquid biopsy method can be used for different types of HPV tumor detection;Australia Scone biological completed a new round of 1.
5 billion yuan Financing.
.
.
Biodiscovery will pay attention to the "medicine" news with you and explore the value of biotechnology! [Drug] progress [drug] progress [drug] progress 1, 1, Baiji Divine anti-PD-1 antibody recently approved a new indication is expected to Baiji Divine anti-PD-1 antibody recently approved a new indication is expected toRecently, Baiji A new indication (CXSS2100030) for the listing of a new indication (CXSS2100030) for the China anti-PD-1 antibody tislelizumab (Bezian) has entered the approval status, which means that the indication is expected to be approved in the near future.
According to a press release issued by BeiGene, the indications that are expected to be approved this time are: treatment of second or third-line locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have undergone disease progression after receiving platinum-based chemotherapy.
 

 

2.

Ruige Pharmaceutical's new generation of CDK2/4/6 small molecule inhibitors was approved for clinical use in the United States

2.
Ruige Pharmaceutical's new generation of CDK2/4/6 small molecule inhibitors was approved for clinical use in the United States 2.

Recently, Regal Pharmaceuticals announced that the clinical study of its next-generation tumor-targeting inhibitor RGT-419B has been approved by the US FDA
.

RGT-419B is a new-generation CDK2/4/6 small molecule inhibitor with an optimized kinase activity profile, which is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors

Recently, Regal Pharmaceuticals announced that the clinical study of its next-generation tumor-targeting inhibitor RGT-419B has been approved by the US FDA

Recently, Tasly announced that it has reached a cooperation from Sutro Biopharma, Inc.
of the United States to obtain the exclusive development and commercialization rights of the antibody-conjugated drug STRO-002 targeting folate receptor alpha (FRα) in mainland China, Hong Kong, Macao and Taiwan.
The transaction amount includes 4000 Ten thousand US dollars down payment and potential development and commercialization milestone payments of up to 345 million US dollars, as well as an agreed percentage of sales commissions
.

Recently, Tasly announced that it has reached a cooperation from Sutro Biopharma, Inc.
of the United States to obtain the exclusive development and commercialization rights of the antibody-conjugated drug STRO-002 targeting folate receptor alpha (FRα) in mainland China, Hong Kong, Macao and Taiwan.
The transaction amount includes 4000 Ten thousand US dollars down payment and potential development and commercialization milestone payments of up to 345 million US dollars, as well as an agreed percentage of sales commissions
.

【Basic Research】【Basic Research】  

1.

Recently, the research team of the Dakar Cancer Institute in Senegal found that ct-HPV DNA detection and the virus pattern characteristics of HPV-related invasive cancer can be achieved by analyzing standard blood samples, regardless of tumor type and virus genotype, all have high levels Sensitivity and specificity

  Recently, Auscom Biotech (Nantong) Co.

Shanghai Vision Pharmaceutical Co.

End reference source: [1] https://mp.
weixin.
qq.
com/s/ulvbWMNRD_T3RalFZv0cfQ [2] https://mp.
weixin.
qq.
com/s/HFx00hwQlEsiyiquGwj5nA Leave a message here